RevenueShares Ultra Dividend ETF

Most Recent

  • uploads///RDUS Revenue Growth
    Company & Industry Overviews

    Taking Stock of Radius Health’s Financial Performance

    In 3Q17, Radius Health (RDUS) generated revenue of $13.4 million. Of this revenue, $3.4 million came from product revenue, which comprises Tymlos sales and licensing revenue.

    By Kenneth Smith
  • uploads///Elacestrant market opportunity
    Company & Industry Overviews

    Taking Stock of Radius Health’s Licensing Agreements

    The market has responded very positively to Radius Health’s recent performance. In the past month, Radius stock has generated a 28% return for its shareholders.

    By Kenneth Smith
  • uploads///RDUS pipeline
    Company & Industry Overviews

    A Strong Pipeline of Drugs Bodes Well for Radius Health

    The drug candidates in Radius Health’s (RDUS) pipeline include an investigational abaloparatide transdermal patch for possible use in treating women with postmenopausal osteoporosis.

    By Kenneth Smith
  • uploads///RDUS Analysts Reco
    Company & Industry Overviews

    Analysts’ Ratings for Radius Health and Its Peers in January

    In April 2017, Radius received FDA approval for its first commercial product, Tymlos. Tymlos was approved for the treatment of postmenopausal women with osteoporosis at a high risk for fracture.

    By Kenneth Smith
  • uploads///chart
    Macroeconomic Analysis

    A Comparative Analysis of PTH and DWAQ

    PTH and DWAQ have followed similar trends in 2015. PTH has a higher beta than DWAQ because it’s a pure sectoral equity fund, and its trend movement is more significant than DWAQ’s.

    By Ivan Kading
  • uploads///chart
    Macroeconomic Analysis

    An Overview of PTH’s Pharmaceutical and Biotechnology Holdings

    PTH is majorly invested in pharmaceutical companies, with 43.2% of its funds invested in pharmaceutical stocks. The biotechnology subsector comes next with a total share of 28.3%.

    By Ivan Kading
  • uploads///Graph Part  Nov
    Company & Industry Overviews

    Moving Averages of XBI’s Holdings Have Improved

    The moving averages of the stocks in the SPDR S&P Biotech ETF (XBI) have seen drastic improvements recently.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    On a Bullish Day, IBB Outperformed XLV

    The iShares Nasdaq Biotechnology ETF (IBB) rose 4.4%, the Health Care Select Sector SPDR ETF (XLV) rose 2.2%, and the SPDR S&P 500 ETF (SPY) moved up by 1.5% on October 15.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    Radius Continued to Fall despite Positive Data on Osteoporosis

    Radius closed at $49.80 on October 13, 2015. During this period, it fell ~34%. Radius is trading below the 20-day, 50-day, and 100-day moving averages.

    By Peter Neil
  • uploads///Part  chart
    Company & Industry Overviews

    ANAC Leads Pharmaceuticals Valuations in the Week Ending July 17

    Anacor Pharmaceuticals (ANAC) with a 71.92% jump in its price for the week ending July 17, 2015, has helped to push the average PVB of the pharmaceutical sector to 11.62.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.